Nisoldipine

Information about Nisoldipine

Nisoldipine is a second generation calcium channel blocker and commonly used antihypertensive agent.

Liver safety of Nisoldipine

Nisoldipine therapy is associated with a low rate of serum enzyme elevations, but has not been specifically linked to instances of clinical apparent acute liver injury.

Mechanism of action of Nisoldipine

Nisoldipine (nye sol' di peen) belongs to the dihydropyridine class of calcium channel blockers (similar to amlopdine, felodipine and nifedipine) and is used predominantly for hypertension. Like other calcium channel blockers, nisoldipine acts by blocking the influx of calcium ions into cardiac and vascular smooth muscle cells during membrane depolarization. This action causes relaxation of arterial smooth muscle cells, resulting in arterial vasodilation and a decrease in cardiac work and oxygen consumption.

FDA approval information for Nisoldipine

Nisoldipine was approved in the United States in 1995 and current indications are for treatment of hypertension. It is available as extended release tablets of 8.5, 17, 25.5 and 34 mg generically and under the commerical name Sular. The recommended dose in adults is 17 mg once daily, adjusting to 17 to 34 mg per day based upon clinical effects and tolerance.

Side effects of Nisoldipine

Like other calcium channel blockers, nisoldipine is generally well tolerated, but side effects can include headache, flushing, dizziness, fatigue, nausea, diarrhea, palpitations, peripheral edema and skin rash.

calcium channel blockers

• amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, verapamil

Antihypertensive agents

• Dailymed label info on Nisoldipine
• FDA Nisoldipine

Nisoldipine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia